BioCentury | Apr 30, 2020
Product Development

NIH competition to encourage COVID-19 diagnostic innovation, pad U.S. testing capacity

As dozens of leading biopharmas, research institutes and health agencies embrace precompetitive coalitions and master protocols to speed development of COVID-19 therapies and vaccines, NIH has created a competition to accelerate diagnostics. The organization today...
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
BC Innovations | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

Preclinical studies showing the utility of CAR T cells outside of cancer are ramping up, and developers have taken notice. But turning the modality into a general-purpose tool will require companies to break through safety...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Week In Review | Feb 22, 2019
Company News

NASA to test Pluristem's PLX cells for space mission-related indications

The NASA Ames Research Center will study the potential of placenta-based PLX cell therapies from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) to prevent and treat medical conditions resulting from space missions in astronauts under a...
BioCentury | Feb 9, 2019
Politics, Policy & Law

Killing Part D rebates

HHS’s proposal to scrap the secret rebates drug manufacturers pay PBMs and health plans in Medicare Part D would help President Donald Trump fulfill promises to reduce drug prices. It would also reduce financial burdens...
BC Innovations | Jan 15, 2019
Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro , patient sample, cell culture and rat studies identified an inhibitor of thrombin-mediated PAR1 activation that could help treat glioblastoma. In tumor samples from patients, PAR1 expression was higher than in...
BC Week In Review | Oct 19, 2018
Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) under a cost recovery program....
BC Extra | Oct 18, 2018
Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) under a cost recovery program....
BC Week In Review | Aug 31, 2018
Clinical News

Prevencio's HART PAD test detects PAD in diabetes patients

Prevencio Inc. (Kirkland, Wash.) said its HART PAD test diagnosed peripheral artery disease (PAD) in a cohort of 94 diabetic patients with 95% accuracy. Data were presented at the European Society of Cardiology meeting in...
Items per page:
1 - 10 of 463